Skip to main content

Trials in Development

This quarter's most recent list of pending trials with general time frames to expected activation. 

The planned and recently activated trials lists below is the most up to date and is dynamically generated from our database. 

Planned trials

ALC9

Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)

CE10

VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma

CO33

Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma: The BATTMAN Trial

HN14

Delayed Reduced Volume and Dose Elective Ratiotherapy (REVERT) in Patients with HNSCC

MD1

CALMS: Combination Therapy with Luspatercept in Lower Risk MDS CTEP approval: 2024AUG27 (date of US Steering Committee Evaluation)

More >>

ME18

Selective Index Node Resection vs Lymph Node Dissection after Neoadjuvant Immunotherapy for Stage IIIB-D Melanoma The Multicentre Selective Lymphadenectomy Trial-3 (MSLT-3)

PAC5

Lanreotide for the Prevention of Postoperative Pancreatic Fistula

SC30

Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial - RATIONAL-PT

SC31

Using SMART to optimize the stepped care delivery of TEMPO – a Tailored, dyadic, wEb-based physical activity and self-Management PrOgram for men with prostate cancer and their caregivers (TEMPO)

SR8

NeoAdjuvant-only or Peri-operative cemiplimab in high-grade localised soft-tissue SARcoma (NAPStAR)

MA42

No Chemotherapy in Intermediate-risk HR + HER2- Early Breast Cancer Treated with Ribociclib (NoLEEta)

Recently activated

BR38

Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer

More >>

HE2

STRIDE (durvalumab + tremelimumab) with Lenvatinib vs STRIDE Alone in Patients with Unresectable Hepatocellular Carcinoma (SLIDE-HCC)

More >>

PR26

Addition of Docetaxel to Androgen Receptor Pathway Inhibitors in Patients with Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response (TRIPLE-SWITCH)

More >>

SKC1

Neoadjuvant Immunotherapy with Response-Adapted Treatment vs Standard-Of-Care Treatment For Resectable Stage III/IV Cutaneous Squamous Cell Carcinoma

More >>

Patients Stories

The BR38 trial testing targeted radiotherapy added to immunotherapy to improve outcomes for lung cancer patients.

The BR38 trial testing targeted radiotherapy added to immunotherapy to improve outcomes for lung cancer patients.

The recently opened BR38 clinical trial is exploring whether adding stereotactic body radiotherapy (SBRT) to the current treatment of immunotherapy (with or without chemotherapy) can improve outcomes for patients with metastatic non-small cell lung cancer (NSCLC) and limited disease progression (oligoprogression).

More >>
 
The BR38 trial testing targeted radiotherapy added to immunotherapy to improve outcomes for lung cancer patients.

The BR38 trial testing targeted radiotherapy added to immunotherapy to improve outcomes for lung cancer patients.

The recently opened BR38 clinical trial is exploring whether adding stereotactic body radiotherapy (SBRT) to the current treatment of immunotherapy (with or without chemotherapy) can improve outcomes for patients with metastatic non-small cell lung cancer (NSCLC) and limited disease progression (oligoprogression).

More >>
 
New trial SKC1 is testing the neoadjuvant addition of an immunotherapy drug for advanced skin cancer

New trial SKC1 is testing the neoadjuvant addition of an immunotherapy drug for advanced skin cancer

The SKC1 skin cancer clinical trial is now open to enrollment across Canada. This study aims to determine whether adding an immunotherapy drug prior to the standard surgical treatment for advanced skin cancer can improve patient outcomes. This study addresses a substantial unmet need in this patient population.

More >>
 
Sarcoma immunotherapy trial SRC8 opens across Canada

Sarcoma immunotherapy trial SRC8 opens accross Canada

The SRC8 clinical trial is now open for enrollment and will investigate whether a combination of immunotherapy and chemotherapy is more effective than chemotherapy alone for adults with advanced sarcoma, specifically undifferentiated pleomorphic or poorly differentiated sarcoma subtypes.

More >>